



**TISSUE THERAPIES**

**ASX RELEASE**

**28 January 2009**

**2009 Non-Renounceable Rights Issue – overseas shareholders**

Please find enclosed an offer document relating to the Tissue Therapies Limited (**Tissue Therapies**) Non-Renounceable Rights Issue for your information only.

Only eligible Shareholders registered as holders of shares at the Record Date of 10 February 2009 with a registered address in Australia or New Zealand may participate in the offer.

The Company considers it unreasonable on this occasion to extend the Rights Issue to Shareholders with a registered address outside of Australia or New Zealand having regard to the costs of complying with legal and regulatory requirements in each of those jurisdictions.

Thank you for your continued support of Tissue Therapies and I trust you understand the Company's position in this matter.

Yours sincerely

**Dr Steven Mercer**  
Managing Director

## **About Tissue Therapies Limited**

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

**More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)**